Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL11039617 | 0.97 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1THRBTSHRTP53 | |
| Trifluoroacetic Acid SCHEMBL30699576 | 0.97 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1THRBTSHRTP53 | |
| Trifluoroacetic Acid SCHEMBL27753577 | 0.97 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1THRBTSHRTP53 | |
| Trifluoroacetic Acid SCHEMBL5583768 | 0.94 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1THRBTSHRTP53 | |
| Trifluoroacetic Acid SCHEMBL30657022 | 0.84 | — | — | |
| Trifluoroacetic Acid SCHEMBL4598430 | 0.84 | — | — | |
| Trifluoroacetic Acid SCHEMBL7814389 | 0.84 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1THRBTSHRTP53 | |
| Trifluoroacetic Acid SCHEMBL2484766 | 0.84 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1THRBTSHRTP53 | |
| Trifluoroacetic Acid SCHEMBL474 | 0.84 | — | — | |
| Trifluoroacetic Acid SCHEMBL31127616 | 0.83 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1THRBTSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | claimed |
| CN-111944104-B | Porous double-template molecularly imprinted polymer microsphere for detecting dengue NS1 protein and application thereof | 华南师范大学 | 2022-06-21 | — | — | CN | claimed |
| CN-111944104-A | Porous double-template molecularly imprinted polymer microsphere for detecting dengue NS1 protein and application thereof | 华南师范大学 | 2020-11-17 | — | — | CN | claimed |
| EP-0570849-B1 | Process for the cleavage of cephalosporin prodrug esters to 7-amino-3-methoxymethylceph-3-em-4-carboxylic acid | HOECHST AG (DE) | 1998-03-25 | — | — | EP | claimed |
| US-5410042-A | Process for the cleavage of cephalosporin prodrug esters to 7-amino-3-methoxymethylceph-3-em-4-carboxylic acid | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-25 | — | — | US | claimed |
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024012519-A1 | PAN-KRAS INHIBITOR | 北京华森英诺生物科技有限公司 | 2024-01-18 | — | — | WO | disclosed |
| CN-117024423-A | Synthetic method of 3, 4-dihydro-isocoumarin-beta-carboline hybrid and analogue thereof | 伊犁师范大学 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023173121-A1 | PHENYL MALEIMIDE LINKER AGENTS | FIREFLY BIO, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-101657437-A | Novel method for preparing levocetirizine and intermediate thereof | KRKA TORVARNA ZDRAVIL D D NOVO | 2010-02-24 | — | — | CN | disclosed |
| US-20090170790-A1 | KETOLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| EP-1807439-A2 | KETOLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006046112-A2 | KETOLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-04 | — | — | WO | disclosed |
| WO-2004112714-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| CN-1214039-A | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM PLC (GB) | 1999-04-14 | — | — | CN | disclosed |
| US-5410042-A | Process for the cleavage of cephalosporin prodrug esters to 7-amino-3-methoxymethylceph-3-em-4-carboxylic acid | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-25 | — | — | US | disclosed |
| US-4165316-A | Process for preparing sulfinyl chlorides from penicillin sulfoxides | ELI LILLY AND COMPANY (US) | 1979-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | ALDH1A1 3778/4885L3MBTL1 4185/4885THRB 195/4885 |
| US-20090170790-A1 | KETOLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | MGAM, HEXA, MGAM2 | ALDH1A1 2673/4885L3MBTL1 2923/4885THRB 2174/4885 |
| US-20240067640-A1 | PHENYL MALEIMIDE LINKER AGENTS | TPX2, H1-4, MAPT | ALDH1A1 4502/4885L3MBTL1 816/4885THRB 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.